aldo-keto reductase family 1 member E2Genealiases: AKR1CL2 · AKRDC1 · HTSP1 · LoopADR · TAKR · hTSP
Q-omics provides the consensus-scored AKR1E2 profile across patient tissues and cancer cell-line models. AKR1E2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, AKR1E2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, AKR1E2 RNA expression shows 15,361 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, THCA, and THYM as cancer lineages where AKR1E2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1E2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1E2 survival associations across molecular data types. AKR1E2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1E2 RNA expression–survival associations across cancer types. High AKR1E2 expression shows unfavorable associations in BRCA, COAD, THCA, ACC, ESCA and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for AKR1E2 RNA expression.
This table summarizes AKR1E2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for AKR1E2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1E2 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, COAD and LUSC. The THCA box plot shows higher AKR1E2 RNA expression in normal versus tumor tissue (log2 FC = −1.900, t-test p < 0.001).
This table shows molecular features associated with AKR1E2 in patient tissues and cancer cell lines. In patient samples, AKR1E2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR1E2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
